About

Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with non-valvular atrial fibrillation.

Anticoagulant reversal should only be considered with life-threatening bleeds, with bleeds that fail to respond to usual measures, and in patients requiring urgent surgery.

Idarucizumab is licensed for dabigatran reversal. The Factor Xa inhibitor andexanet alfa has recently been licensed in the US for reversal of rivaroxaban, apixaban and edoxaban.

Articles

Anticoagulation in Atrial Fibrillation

Citation:

Arrhythmia & Electrophysiology Review 2012;1(1):12–6

NOACs and Dual Antiplatelet Therapy

Published:

01 May 2015

Citation:

Arrhythmia & Electrophysiology Review 2015;4(1 Suppl 1):7-8

Antidotes or Reversibility Agents – Are they Needed?

Published:

01 May 2015

Citation:

Arrhythmia & Electrophysiology Review 2015;4(1 Suppl 1):6-7